The German government has ordered 100 million doses of BA.1 and BA.4/5 bivalent vaccines at a cost of 2.5 billion Euros, and almost nobody wants them. An amusing Welt article chronicles the scenes unfolding at our deserted regional vaccination centres, which for some reason are still open:
Michael Hubmann did not expect that so few would come. Only 85 people had themselves vaccinated against Covid-19 on Thursday in Fürth in Middle Franconia, a district with 120,000 inhabitants. “We’ve tried to make it as easy as possible for people,” says Hubmann, a paediatrician who is coordinating the vaccination campaign. He explains that vaccinations were offered simultaneously in two shopping centres, a bus, a home for the elderly and in a former shop in the pedestrian zone. “Yet hardly anyone wanted to have the fourth dose.”
The medical bureaucrats are baffled, just baffled:
“Unfortunately, interest in the fourth dose has been pretty low so far,” says Markus Beier, Chairman of the German Association of General Practitioners. At the same time, he says it’s important that people over 60 and those with previous illnesses in particular protect themselves with a further dose. “There is uncertainty among the population as to what further vaccinations will achieve. But they still strengthen protection against severe outcome.”
Meanwhile, vast quantities of vaccine are expiring. At the end of August alone, 3.9 million doses of Moderna and another 700,000 doses of Novavax had to be binned.
The chart above tells the whole sordid story of our recent experiment with mass vaccination. Demand for this snake oil was highest in the beginning, before anybody had any direct experience with it; and in the Fall, when the government tied vaccination to specific social privileges. As overt vaccinator coercion has faded and millions of people have tried these doubtful elixirs for themselves, interest has all but entirely evaporated. This is the ultimate vindication for all those who have been saying that the vaccines are lousy overhyped pharmaceuticals with a bad side-effect profile. A safe and effective product would only gain momentum with the population. It took less than two years for these to wear out their welcome.